30.82
過往表現並非未來業績的可靠指標
Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, a novel inhibitor of the activation of latent myostatin that has completed the Phase II clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
差价合约 (CFD) 是一种复杂的金融工具，利用杠杆交易虽然可能放大收益，但同样也会加剧亏损风险，导致资金快速流失。数据显示，79.58% 的散户投资者在使用该提供商服务进行差价合约交易时出现账户亏损。在进行交易之前，请确保您充分了解差价合约的运作机制，并仔细评估自己是否有能力承担资金亏损的高风险。
评分与评论
评分与评论
